# Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma

> **NCT00004184** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Alabama at Birmingham** · enrollment: 50 (estimated)

## Conditions studied

- Melanoma (Skin)

## Interventions

- **BIOLOGICAL:** monoclonal antibody 4B5 anti-idiotype vaccine
- **BIOLOGICAL:** sargramostim
- **DRUG:** alum adjuvant

## Key facts

- **NCT ID:** NCT00004184
- **Lead sponsor:** University of Alabama at Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1998-08
- **Primary completion:** 2001-06
- **Final completion:** 2001-06
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2013-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004184

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004184, "Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00004184. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*